Skip to main content

Mauro David J's Form 4 filing

Prelude Therapeutics Inc (PRLD) · filed Aug 9, 2021

Accession no.
0001209191-21-050404
Filed
Aug 9, 2021
Trade date
Aug 5, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $466.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mauro David JCIK 0001621172Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 5, 2021Common StockMOption exerciseAcquired+15,000$1.89+$28,35015,000Direct
Aug 5, 2021Common StockSSaleDisposed−6,116$29.93−$183,051.888,884Direct
Aug 5, 2021Common StockSSaleDisposed−2,063$31.03−$64,014.896,821Direct
Aug 5, 2021Common StockSSaleDisposed−6,721$32.15−$216,080.15100Direct
Aug 5, 2021Common StockSSaleDisposed−100$32.63−$3,2630Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 5, 2021Common StockMOption exerciseDisposed−15,000$0.00$0167,610Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)